Merck responds to Arcoxia approvable letter

Merck has responded to an FDA “approvable” letter for Arcoxia (etoricoxib), an investigational selective Cox-2 inhibitor, with results of the MEDAL program. The company is hoping Arcoxia can take the place of Vioxx.

You must be a registered member of MMM to post a comment.

Next Article in Legal/Regulatory